Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
- PMID: 15750627
- DOI: 10.1038/sj.onc.1208518
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
Erratum in
- Oncogene. 2007 Oct 11;26(46):6684. Furasato, Bungo [corrected to Furusato, Bungo]
Abstract
Transcription factors encoded by the ETS family of genes are central in integrating signals that regulate cell growth and differentiation, stress responses, and tumorigenesis. This study, analysing laser microdissected paired benign and malignant prostate epithelial cells from prostate cancer (CaP) patients (n=114; 228 specimen) by GeneChip and quantitative real-time RT-PCR, identifies ETS-related gene (ERG), a member of the ETS transcription factor family, as the most frequently overexpressed proto-oncogene in the transcriptome of malignant prostate epithelial cells. Combined quantitative expression analysis of ERG with two other genes commonly overexpressed in CaP, AMACR and DD3, revealed overexpression of at least one of these three genes in virtually all CaP specimen (54 of 55). Comprehensive evaluation of quantitative ERG1 expression with clinicopathological features also suggested that ERG1 expression level in prostate tumor cells relative to benign epithelial cells is indicator of disease-free survival after radical prostatectomy.
Similar articles
-
ERG upregulation and related ETS transcription factors in prostate cancer.Int J Oncol. 2007 Jan;30(1):19-32. Int J Oncol. 2007. PMID: 17143509
-
Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.J Zhejiang Univ Sci B. 2007 Dec;8(12):853-9. doi: 10.1631/jzus.2007.B0853. J Zhejiang Univ Sci B. 2007. PMID: 18257117 Free PMC article.
-
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547. PLoS One. 2010. PMID: 20479932 Free PMC article.
-
[The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].Yi Chuan. 2011 Feb;33(2):117-22. doi: 10.3724/sp.j.1005.2011.00117. Yi Chuan. 2011. PMID: 21377967 Review. Chinese.
-
Molecular prostate cancer pathology: current issues and achievements.Scand J Urol Nephrol Suppl. 2005 May;(216):82-93. doi: 10.1080/03008880510030950. Scand J Urol Nephrol Suppl. 2005. PMID: 16019760 Review.
Cited by
-
TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.J Clin Pathol. 2007 Nov;60(11):1185-6. doi: 10.1136/jcp.2007.046557. J Clin Pathol. 2007. PMID: 17965219 Free PMC article. Review.
-
Advances in Prostate Cancer Biomarkers and Probes.Cyborg Bionic Syst. 2024 Jun 27;5:0129. doi: 10.34133/cbsystems.0129. eCollection 2024. Cyborg Bionic Syst. 2024. PMID: 40353136 Free PMC article. Review.
-
Precision medicine applications in prostate cancer.Ther Adv Med Oncol. 2018 Jun 18;10:1758835918776920. doi: 10.1177/1758835918776920. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 29977347 Free PMC article. Review.
-
Clinical Applications of Molecular Biomarkers in Prostate Cancer.Cancers (Basel). 2020 Jun 12;12(6):1550. doi: 10.3390/cancers12061550. Cancers (Basel). 2020. PMID: 32545454 Free PMC article. Review.
-
Clinical Biofluid Assays for Prostate Cancer.Cancers (Basel). 2023 Dec 28;16(1):165. doi: 10.3390/cancers16010165. Cancers (Basel). 2023. PMID: 38201592 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous